Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 50Small Cell Lung Carcinoma 23Breast Neoplasms 17Sarcoma 16Carcinoma, Hepatocellular 10Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Neoplasm Metastasis 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Pheochromocytoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

anlotinib 2penpulimab 1Laparoscopy 1Injections, Spinal 1Injections, Epidural 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Gynecological Cancer × anlotinib × Clear all
NCT05028504 2023-12-27

ALTER-GO-020

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
86 enrolled

Gynecological Cancer

NCT04236362 2021-01-12

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
90 enrolled

Gynecological Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡